Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SNB 011

Next Previous
X
Search
Drug Profile

SNB 011

Alternative Names: Airnecflu®; Pentarlandir™; Pentarlandir™ Ultrapure and Potent Tannic Acid; Pentarlandir™ UPPTA; SNB-01; SNB-011

Latest Information Update: 02 Aug 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SyneuRx International (Taiwan) corp
  • Class Anti-inflammatories; Antivirals; Biopolymers; Small molecules
  • Mechanism of Action Coronavirus 3C-like proteinase inhibitors; Cytokine inhibitors; D amino acid oxidase inhibitors; Serine protease inhibitors; Virus internalisation inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II COVID 2019 infections
  • Preclinical Anxiety disorders; Depressive disorders; Memory disorders

Most Recent Events

  • 02 Aug 2022 Preclinical trials in COVID-2019 infections in Taiwan (Inhalation) (SyneuRx pipeline, August 2022)
  • 02 Aug 2022 SyneuRx plans a first-in-human trial for COVID-2019 infections in the second half of 2022 (SyneuRx pipeline, August 2022)
  • 31 Jul 2022 Efficacy and safety data from a phase II trial for COVID-2019 infection released by SyneuRx International
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top